Valid until: 06-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/are-two-pathways-better-than-one-experts-discuss-the-role-of-ang2-vegfa-inhibition-in-retinal-vascular-disease/16620/
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
=Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Nikki Glaser Podcast
Every week comedian and infamous roaster Nikki Glaser provides a fun, fast-paced, and brutally honest look into current pop-culture and her own personal life.